No Data
China National Medicines H1 Profit Ticks Up 2%; Shares Down 4%
Declining Stock and Solid Fundamentals: Is The Market Wrong About China National Medicines Corporation Ltd. (SHSE:600511)?
Summary of China National Medicines Corporation's 2024 Interim Report
China National Medicines Corporation 2024 Interim Report
China National Medicines Corporation (600511.SH): The net income for the first half of the year was 1.001 billion yuan, an increase of 1.62% year-on-year.
GeLongHui, August 21st. China National Medicines Corporation (600511.SH) released the interim report for the first half of 2024, achieving revenue of 24.757 billion yuan, a 2.55% year-on-year increase; net income attributable to shareholders of the listed company was 1.001 billion yuan, a 1.62% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.003 billion yuan, a 5.46% year-on-year increase; basic earnings per share were 1.3261 yuan. The company's main business is medical distribution. With the gradual deepening of medical reforms, the emergence of medical policies, and the stable development of regional medical treatment, the company seizes market opportunities.
Express News | Corrected-China National Medicines (Not Sinopharm Group Co Ltd) : Has No Business Dealings With Shanxi Osteorad Biomaterial Co (Not Shanxi Aorui Biomaterials)
China National Medicines (SHSE:600511) Might Be Having Difficulty Using Its Capital EffectivelyNo Data
